Actavis sees 2Q loss but Warner deal has reached final stages
This article was originally published in Scrip
Executive Summary
Generic drug developer Actavis has posted a second quarter loss of $4.27 per share, despite reporting a 47% increase in revenues, because of "restructuring costs." The Parsippany, New Jersey-based firm, previously known as Watson Pharmaceuticals, said the costs arose from the 2009 acquisition of UK drug maker Arrow. The combined assets were subsequently restructured from one global reporting unit into four new reporting units.